CURRENT REPORT 40/2020
21 October 2020

Revision of the Company's research project pipeline

The Management Board of Ryvu Therapeutics S.A., with its registered office in Krakow ("Company"), hereby announces that on October 20, 2020, made a decision to revise the preclinical projects' pipeline of the Company. As a consequence, the Company shall stop the development of two projects: a dual adenosine receptor antagonist (A2A/A2B) and the project in the area of synthetic lethality (SMARCA2). The above decision was made after consultation with the Supervisory Board of the Company.

When making this decision, the Management Board was guided by the analysis of the scientific results obtained during the research and development activities carried out so far, as well as the development prospects of projects in further stages. An analysis of the current and expected competitive environment, including the results of research published by competitors developing compounds targeting the above-mentioned protein targets, was also carried out.

As a result of the pipeline's revision, the Company will be able to concentrate its human and financial resources, including proceeds from the series I follow-up offering, on the SEL120 project, currently in Phase I clinical trials as well as the remaining preclinical projects, and assign financing to newly initiated discovery and development projects in the area of synthetic lethality. The Company has already started working on new, confidential targets, which in its opinion, will have a greater chance to develop into new, first-in-class therapeutic options for the patients, with a good preclinical and clinical development possibility, and provide an additional partnering opportunities with biotech and pharma companies.

Legal basis: art. 17.1 Market Abuse Regulation

Representatives:

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka – Vice-president of the Management Board